Endoscopy 2020; 52(S 01): S7
DOI: 10.1055/s-0040-1704031
ESGE Days 2020 oral presentations
Thursday, April 23, 2020 10:30 – 12:00 Colorectal Cancer (CRC) Screening (WEO-ESGE joint session) Ecocem Room
© Georg Thieme Verlag KG Stuttgart · New York

POST-COLONOSCOPY COLORECTAL CANCER IN LYNCH SYNDROME IS ASSOCIATED WITH QUALITY ISSUES DURING SURVEILLANCE

Autor*innen

  • A Sanchez Garcia

    1   Hospital Clinic of Barcelona, Barcelona, Spain
  • M Navarro

    2   Institut Catala d’Oncologia, Hospitalet de Llobregat, Spain
  • VH Roos

    3   Amsterdam UMC Universitair Medische Centra, Amsterdam, Netherlands
  • M Pineda

    4   Institut Catala d’Oncologia, Barcelona, Spain
  • B Caballol

    1   Hospital Clinic of Barcelona, Barcelona, Spain
  • L Moreno

    1   Hospital Clinic of Barcelona, Barcelona, Spain
  • T Ocaña

    1   Hospital Clinic of Barcelona, Barcelona, Spain
  • F Rodriguez-Moranta

    5   Hospital Universitario de Bellvitge, Hospital de Llobregat, Spain
  • L Rodriguez-Alonso

    5   Hospital Universitario de Bellvitge, Hospital de Llobregat, Spain
  • TRy Cajal

    6   Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
  • G Llort

    7   Instituto Oncologico del Valles, Terrasa-Sabadell, Spain
  • MD Pico

    8   Hospital General Universitario de Alicante, Alicante, Spain
  • R Jover

    8   Hospital General Universitario de Alicante, Alicante, Spain
  • Adria Lopez Fernandez

    9   Hospital Universitario Vall d’Hebron, Barcelona, Spain
  • E Martinez de Castro

    10   Hospital Universitario Marques de Valdecilla, Santander, Spain
  • MJ Lopez-Arias

    10   Hospital Universitario Marques de Valdecilla, Santander, Spain
  • C Alvarez

    11   Hospital del Mar, Barcelona, Spain
  • X Bessa

    11   Hospital del Mar, Barcelona, Spain
  • L Rivas

    12   Complexo Hospitalario Universitario de Orense, Orense, Spain
  • J Cubiella

    12   Complexo Hospitalario Universitario de Orense, Orense, Spain
  • D Rodriguez-Alcalde

    13   Hospital de Mostoles, Mostoles, Spain,
  • A Dacal

    14   Hospital Universitario Lucus Augusti, Lugo, Spain
  • M Herraiz

    15   Clinica Universidad de Navarra, Pamplona, Spain
  • C Garau

    16   Hospital Universitari de Son Llatzer, Palma de Mallorca, Spain
  • L Bujanda

    17   Hospital Universitario de Donostia, Donostia, Spain
  • L Cid

    18   Complexo Hospitalario Universitario de Vigo, Vigo, Spain
  • C Poves

    19   Hospital Clinico San Carlos, Madrid, Spain
  • M Garzon

    20   Hospital Virgen del Rocio, Sevilla, Spain
  • A Pizarro

    20   Hospital Virgen del Rocio, Sevilla, Spain
  • I Salces

    21   Hospital 12 de Octubre, Madrid, Spain
  • M Ponce

    22   Hospital Universitario de la Fe de Valencia, Valencia, Spain
  • M Carrillo-Palau

    23   Hospital Universitario de Canarias, La Laguna, Spain
  • E Aguirre

    24   Hospital Quironsalud de Zaragoza, Zaragoza, Spain
  • E Saperas

    25   Hospital General de Catalunya, Sant Cugat del Valles, Spain
  • A Suarez

    26   Hospital Universitario Central de Asturias, Oviedo, Spain
  • V Piñol

    27   Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain
  • S Carballal

    1   Hospital Clinic of Barcelona, Barcelona, Spain
  • L Rivero-Sanchez

    1   Hospital Clinic of Barcelona, Barcelona, Spain
  • J Balmaña

    9   Hospital Universitario Vall d’Hebron, Barcelona, Spain
  • J Brunet

    28   Institut Catala d’Oncologia, Girona, Spain
  • A Castells

    1   Hospital Clinic of Barcelona, Barcelona, Spain
  • E Dekker

    3   Amsterdam UMC Universitair Medische Centra, Amsterdam, Netherlands
  • M Pellise

    1   Hospital Clinic of Barcelona, Barcelona, Spain
  • G Capella

    4   Institut Catala d’Oncologia, Barcelona, Spain
  • M Serra-Buriel

    29   Center for Research in Health and Economics, UPF, Barcelona, Spain
  • L Moreira

    1   Hospital Clinic of Barcelona, Barcelona, Spain
  • F Balaguer

    1   Hospital Clinic of Barcelona, Barcelona, Spain
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
23. April 2020 (online)

 

Aims To assess the effect of quality endoscopic factors on the development of PCCRC during surveillance in LS mutation carriers.

Methods Multicenter study with 25 high-risk CRC clinics from Spain and 1 from The Netherlands. Demographic, genetics, cancer history, and surveillance protocols from patients LS carriers of verified pathogenic mutations(n=1,746) have been prospectively collected between 2015- 2019. For the current analysis, we focused on healthy-carriers(HC) defined as carriers without CRC prior or in the index colonoscopy. To assess the effect of colonoscopy on PCCRC incidence we evaluated the report of every surveillance colonoscopy(n=3,284). We compared colonoscopies previous to PCCRC with colonoscopies of carriers without cancer. Quality colonoscopy parameters(completeness, bowel-preparation, scope definition and enhancement techniques), time-intervals and findings from a previous colonoscopy were analyzed. Multivariate logistic-regression was performed to identify CRC risk factors.

Results We included 893 HC, 596(63.7%) female, with a median age of 50.5±14.8 years, a median colonoscopy follow-up of 6.3±4.2 years and 4.8±2.7 colonoscopies. The distribution per gene was: 285(31.9%)MLH1, 316(35.4%)MSH2, 212(23.7%) MSH6 and 80(9%) PMS2 carriers. During surveillance 48(5.4%) PCCRC were diagnosed [17(35.4%) MLH1, 24(50%) MSH2, 6(12.5%) MSH6 and 1(2.1%)PMS2]. The mean age at diagnosis was 51.1±10.6 years, the mean follow-up 5.8±5.5 years, 32(66.7%). When analyzing quality colonoscopy indicators, a previous incomplete colonoscopy and previous colonoscopy performed with standard definition appeared as independent risk factors of PCCRC [OR=6.7(95%CI 1.4-33);p0.018 and OR=5.9(95%CI 1.41-25); p0.015]. Besides, an interval between colonoscopies of more than 36 months, or an advanced adenoma in the previous colonoscopy increased more than 4 times the risk of PCCRC[OR=4.1 (95%IC 1.7-9.8);p0.002 and OR=4.16 (95%CI 1.6-10.6);p0.003].

Conclusions PCCCR incidence is associated with quality issues in LS carriers under surveillance colonoscopy. High quality colonoscopy and appropriate interval (< 36 months) should be strongly advised. Patients with an advanced adenoma may benefit of shorter interval between colonoscopies.